Glycosyn develops products based on human milk oligosaccharides (hMOS), which are molecules found naturally in human milk with benefits to the human gut microbial ecology. Glycosyn develops hMOS through proprietary biosynthesis processes in partnership with Ginkgo Bioworks. This process incorporates microbial engineering and cellular fermentation to synthesize hMOS at scale and more affordably then by chemical or enzymatic synthesis. In 2019, Ginkgo invested $14,000,000 in Glycosyn to scale the production of hMOS for a suite of products.